{"organizations": [], "uuid": "7393104ab48f1bf282a96889ba26fdf102934ec2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/cipla-results/update-1-indias-cipla-q3-profit-rises-but-below-estimates-idUSL4N1PX3C8", "country": "US", "domain_rank": 408, "title": "UPDATE 1-India's Cipla Q3 profit rises, but below estimates", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-07T11:33:00.000+02:00", "replies_count": 0, "uuid": "7393104ab48f1bf282a96889ba26fdf102934ec2"}, "author": "", "url": "https://www.reuters.com/article/cipla-results/update-1-indias-cipla-q3-profit-rises-but-below-estimates-idUSL4N1PX3C8", "ord_in_thread": 0, "title": "UPDATE 1-India's Cipla Q3 profit rises, but below estimates", "locations": [], "entities": {"persons": [], "locations": [{"name": "united states", "sentiment": "none"}, {"name": "india", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "cipla", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "cipla ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 34 AM / in 9 minutes UPDATE 1-India's Cipla Q3 profit rises, but below estimates Reuters Staff \n* Q3 profit 4.01 bln rupees vs. est. 4.44 bln rupees \n* Domestic revenue up 15 pct (Adds details) \nFeb 7 (Reuters) - Cipla Ltd, India’s fourth-largest drugmaker by revenue, said third-quarter net profit rose 7 percent on strong domestic sales, but fell short of analysts’ estimates. \nNet profit attributable to shareholders climbed to 4.01 billion rupees ($62.54 million) in the quarter ended Dec. 31, from 3.75 billion rupees a year earlier. bit.ly/2C1Sg7w \nThat compared with an average estimate of 4.44 billion rupees in profit drawn from 18 analysts polled by Thomson Reuters I/B/E/S. \nIncluding a one-off positive impact of 1.07 billion rupees due to recalculation of deferred tax assets and liabilities on account of the tax reforms in the United States, profit rose about 25 percent from a year earlier, the company said. \nRevenue from India, its biggest market, rose 15 percent to 16.01 billion rupees. Domestic revenue accounted for more than a third of the total revenue, which rose 7 percent to 39.14 billion rupees. \nRevenue from North America fell 2 percent due to ongoing pricing pressures in the generics market because of increased competition. ($1 = 64.1150 Indian rupees) (Reporting by Jessica Kuruthukulangara in Bengaluru; Editing by Christopher Cushing and Subhranshu Sahu)", "external_links": [], "published": "2018-02-07T11:33:00.000+02:00", "crawled": "2018-02-07T11:52:13.001+02:00", "highlightTitle": ""}